Literature DB >> 20680254

Bilateral anterior uveitis secondary to erlotinib.

Lik Thai Lim, Robert Alexander Blum, Chee Peng Cheng, Abdul Hanifudin.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20680254     DOI: 10.1007/s00228-010-0873-7

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


× No keyword cloud information.
  2 in total

Review 1.  Epidermal growth factor receptor tyrosine kinase as a target for anticancer therapy.

Authors:  E Raymond; S Faivre; J P Armand
Journal:  Drugs       Date:  2000       Impact factor: 9.546

2.  Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer.

Authors:  Román Pérez-Soler; Abraham Chachoua; Lisa A Hammond; Eric K Rowinsky; Mark Huberman; Daniel Karp; James Rigas; Gary M Clark; Pedro Santabárbara; Philip Bonomi
Journal:  J Clin Oncol       Date:  2004-08-15       Impact factor: 44.544

  2 in total
  5 in total

1.  Bilateral acute anterior uveitis: a rare ocular side effect of erlotinib.

Authors:  Sarah Chan; Elizabeth Ahern; Sarah Chaudhry; Brett Hughes
Journal:  BMJ Case Rep       Date:  2019-12-15

Review 2.  Ocular Toxicity of Targeted Anticancer Agents.

Authors:  Blake H Fortes; Prashant D Tailor; Lauren A Dalvin
Journal:  Drugs       Date:  2021-03-31       Impact factor: 9.546

3.  Erlotinib-associated severe bilateral recalcitrant keratouveitis after corneal EDTA chelation.

Authors:  Zimei Zhou; Kumar Sambhav; K V Chalam
Journal:  Am J Ophthalmol Case Rep       Date:  2016-06-03

4.  Bilateral acute simultaneous onset anterior uveitis presumed secondary to erlotinib: A report of two cases.

Authors:  Kendra A Klein; Christopher G Azzoli; Lana M Rifkin
Journal:  Am J Ophthalmol Case Rep       Date:  2016-09-10

5.  Anterior Uveitis Caused by Ocular Side Effects of Afatinib: A Case Report.

Authors:  Daisuke Todokoro; Hirotaka Itakura; Takashi Ibe; Shoji Kishi
Journal:  Case Rep Ophthalmol       Date:  2016-02-04
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.